Drug · DIN 02564483
TAKHZYRO
2 ML PREFILLED PEN
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since April 20, 2026; first marketed April 20, 2026.
- Drug Identification Number (DIN)
- 02564483
- Company (DIN owner)
- Takeda Canada IncorporatedToronto, Ontario, Canada
- Schedule
- Prescription; Schedule D
- Dosage form
- Solution
- Route
- Subcutaneous
- Therapeutic class (ATC)
- Lanadelumab B06AC05
- Class
- Human
- Record last updated
- July 30, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| LANADELUMAB | 300 MG | 2 ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- January 9, 2026: NOC 36715Supplement to a New Drug Submission (SNDS) · New presentation. Updates to the Product Monograph
Other DINs named TAKHZYRO
- DIN 02480948 · Marketed
- DIN 02505614 · Marketed
- DIN 02566257 · Approved